This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors | MicrobiomeTrials
← Back to trials NCT05687123
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors Recruiting PHASE1 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2024-08-14Est. Completion: 2026-12-14
Enrollment target: 24 participantsLocations City of Hope Comprehensive Cancer Center, Duarte, California, United States UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States Memorial Hospital East, Shiloh, Illinois, United States Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters, Missouri, United States Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States Washington University School of Medicine, St Louis, Missouri, United States Siteman Cancer Center-South County, St Louis, Missouri, United States Siteman Cancer Center at Christian Hospital, St Louis, Missouri, United States University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada Other microbiome trials you might be interested in Pancreatic Neuroendocrine Tumor (pNET) Extra-Pancreatic Neuroendocrine Tumor (epNET)
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants…
Birmingham, United States Est. completion Jun 30, 2029
Neuroendocrine Tumors
Neuroendocrine tumours (NETs) are slow growing cancers, which commonly present as metastatic incurable disease. Some neu…
Sydney, Australia Est. completion Sep 2027
Metastatic Lung Small Cell Carcinoma Metastatic Malignant Solid Neoplasm Metastatic Neuroendocrine Carcinoma Metastatic Pancreatic Adenocarcinoma Stage III Lung Cancer AJCC v8 Stage III Pancreatic Cancer AJCC v8 Stage IV Lung Cancer AJCC v8 Stage IV Pancreatic Cancer AJCC v8 Unresectable Lung Small Cell Carcinoma Unresectable Malignant Solid Neoplasm Unresectable Neuroendocrine Carcinoma Unresectable Pancreatic Adenocarcinoma
This phase I trial tests the safety, side effects and best dose of BAY 1895344 when given together with usual chemothera…
Phoenix, United States Est. completion Feb 15, 2025